Abstract
Preoperative hypofractionated radiotherapy 5x5 Gy for five consecutive days, and then immediate surgery in patients with locally advanced soft tissue sarcomas (STS) showed a good local control rate and treatment tolerance. Myxoid liposarcoma (MLPS) is highly radiosensitive as compared with other STS, thus a longer gap between the end of RT and surgery may increase the local efficacy and allow to obtain better pathological response rate. The main objective of the study was to assess the safety of 5x5 Gy hypofractionated preoperative RT with prolonged gap (6-8 weeks) to surgery in patients with locally advanced primary MLPS. In this single-arm prospective clinical trial. Patients with locally advanced MLPS underwent preoperative 5x5 Gy RT with 6-8 weeks gap between RT end and surgery from April 2015 to January 2019. The primary endpoint of the study was the rate of perioperative wound healing complications. The secondary endpoints were the pathological response according to the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group recommendations (EORTC-STSBG) and local control rate at 5 years. From April 2015 until February 2019 29 patients with primary MLPS finished the whole planned protocol treatment. All of the patients had the tumors located in the lower limb. The median tumor size was 16 cm. The median follow-up time was 13 months. Perioperative wound complications occurred in 9 patients (31%). 6 patients (21%) required medical intervention (antibiotics or wound revision, grade 2 or higher according to Common Terminology Criteria for Adverse Events version 4.03). These results are similar (32.4%) to our historical controls of 272 patients with advanced STS who were treated with 5x5 Gy RT and immediate surgery. R0 margins were achieved in all but two patients (7%) who had R1 resection margin. None of the patients had local recurrence and four patients (14%) developed distant metastases at the moment of analysis (February 2019). The pathological response category according to the EORTC-STSBG recommendations were B (3.5%), C (20.7%), D (34.5%) and E (41.38%). Preoperative hypofractionated RT with the prolonged gap between the RT and surgery is a reasonable approach to MLPS treatment providing a low rate of perioperative complications and good local control.
Highlights
Myxoid liposarcoma (MLPS) has been reported to be more radiosensitive compared with other soft tissue sarcomas
The only factors having a significant impact on the disease-free survival (DFS) were the grade (p = 0.00074, by log-rank test) (Figure 1) of the tumor and the percentage of round cell component (RCC) (p = 0.009; HR = 1.270 per 1% change; 95%CI 1.063–1.518)
Our study showed that hypofractionated RT is efficient, safe, and feasible in patients with MLPS who are qualified for the preoperative treatment
Summary
Myxoid liposarcoma (MLPS) has been reported to be more radiosensitive compared with other soft tissue sarcomas. The main objective of the study was to assess the efficacy of hypofractionated radiotherapy (RT) in the preoperative setting in patients with locally advanced primary MLPS. Results: 29 patients (pts) were included, all had tumors located on the lower limb. Conclusion: Preoperative hypofractionated RT with a prolonged gap between RT and surgery is a feasible method of the management of MLPS, providing a good local control and low rates of treatment toxicity. MLPS is localized in the deep soft tissue of the extremities, usually the proximal thigh [1,2]. Pathological findings show a lesion composed of uniform, round, or oval primitive nonlipogenic mesenchymal cells with lipoblasts gathered peripherally or near the blood vessels, surrounded by myxoid stroma [3]. Diagnosis of MLPS can be confirmed by the finding of a specific chromosomal translocation t(12;16)(q13;p11), detected in more than 95% of cases, which results in fusion of DDIT3 (CHOP) gene and FUS (TLS) gene [4,5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.